Pembrolizumab (Keytruda) received an accelerated approval for adult and pediatric patients with refractory classical Hodgkin lymphoma or those who have relapsed after at least 3 lines of therapy.
Merck has announced that its programmed death-1 inhibitor, pembrolizumab (Keytruda), has been approved for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL) or those who have relapsed after at least 3 lines of therapy. This is an accelerated approval for the drug—proved clinical benefit from confirmatory trials will ensure continued approval.
The approval was based on results from the Keynote-087 trial, which recruited 210 patients with relapsed/refractory cHL, who:
The primary trial outcomes being measured included overall response rate (ORR), percentage of participants with at least 1 adverse event (AE), and percentage of participants discontinuing their study due to adverse events. Secondary outcomes were complete response rate (CRR), progression-free survival, duration of response, and overall survival.
At a median follow-up of 9.4 months, ORR was 69% (95% CI, 62—75) with 200 mg pembrolizumab administered every 3 weeks. CRR was 22% and the partial remission rate was 47%. Of the 145 patients who responded to treatment, the median duration of response was 11.1 months.
Only 5% of patients discontinued treatment due to AEs, but treatment was interrupted in another 26% due to AEs. Most frequent serious AEs, observed in 16% of patients, included pneumonia, pneumonitis, pyrexia, dyspnea, graft-versus-host disease (GVHD), and herpes zoster. Of 2 patients who died from causes other than disease progression, 1 died from GVHD and the other from septic shock.
The pediatric approval comes from data extrapolated from a pediatric melanoma trial.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More